News Bayer adds menopause drug to pipeline with KaNDy acquisition Bayer is to buy UK-based KaNDy Therapeutics in a deal worth more than $800 million, adding the biotech’s menopause drug to its women’s health pipeline.
News UK's KaNDy Therapeutics funds mid-stage trial of HRT 'replac... Biotech hopes for IPO or big pharma deal to fund phase 3
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.